Introduction
============

Mild cognitive impairment (MCI) is a transitional state between normal aging and Alzheimer's disease (AD).[@b1-cia-12-1941],[@b2-cia-12-1941] Approximately 18.5% of Chinese people over the age of 55 years were estimated to have MCI.[@b3-cia-12-1941] In fact, patients with MCI represented a conversion rate of 10%--15% per year for developing AD.[@b4-cia-12-1941],[@b5-cia-12-1941] Therefore, discussing the associations between the risk factors and MCI susceptibility is of great significance.

The apolipoprotein E (ApoE) gene, located on the chromosome 19q13, is closely related to MCI and AD.[@b6-cia-12-1941],[@b7-cia-12-1941] ApoE protein plays a vital role in the transport of lipid and cholesterol in the central nervous system (CNS).[@b8-cia-12-1941] ApoE gene polymorphism has three common alleles: *ε*2, *ε*3, and *ε*4, which determine three homozygous (*ε*2/*ε*2, *ε*3/*ε*3, and *ε*4/*ε*4) and heterozygous (*ε*2/*ε*4, *ε*3/*ε*4, and *ε*2/*ε*3) genotypes.[@b9-cia-12-1941] Of those, ApoE *ε*3 allele is the most prevalent, followed by *ε*4 and *ε*2 alleles.[@b10-cia-12-1941] The ApoE *ε*4 allele has been highly associated with MCI;[@b11-cia-12-1941],[@b12-cia-12-1941] its presence is associated with the elevated serum *β*-amyloid and age-related cognitive decline.[@b13-cia-12-1941],[@b14-cia-12-1941] In addition, it is well known that *ε*4 allele was associated with an increased risk of AD.[@b15-cia-12-1941]

To date, numerous studies have been conducted to estimate the association between ApoE polymorphism and MCI susceptibility. However, the reports still conflict. The sample sizes of the published studies have been relatively small, and individual study may lack powerful power to obtain a more reliable conclusion. In addition, no meta-analysis was performed to explore those associations. Therefore, we conducted a comprehensive meta-analysis to clarify those varying associations.

Materials and methods
=====================

Search strategy
---------------

All published studies assessing the association of ApoE polymorphism with MCI susceptibility were identified by comprehensive literature searches of the PubMed, EMBASE, Wanfang, VIP, and CNKI (China National Knowledge Infrastructure) databases from May 2002 to October 2016. The key terms used for searching are ("MCI" OR "mild cognitive impairment") AND ("ApoE" OR "apolipoprotein E") AND ("polymorphism" OR "variant"). Moreover, the references in all selected studies were searched for other potential studies.

Inclusion and exclusion criteria
--------------------------------

Studies included in our meta-analysis must meet the following criteria: 1) case--control or cohort study; 2) estimate the association between ApoE polymorphism and MCI susceptibility; 3) allelic and genotype frequencies are available for calculating odds ratios (ORs) and corresponding 95% confidence intervals (95% CIs); 4) genotype distribution of control must be in Hardy--Weinberg equilibrium (HWE); 5) not overlapping samples; and 6) studies with full-text. The exclusion criteria for the studies were as follows: case reports, reviews, in vitro studies, clinical trials, incomplete genotype data, and meta-analysis.

Data extraction
---------------

Relevant data from each selected studies, including the first author, publication year, country of region, genotyping methods, sample size, genotype distributions and allele frequencies of cases and controls, and the diagnosis criteria of MCI, were extracted independently by two investigators (TH and WSD).

Statistical analysis
--------------------

The ORs and corresponding 95% CIs were used to evaluate the relationship between ApoE polymorphism and MCI susceptibility. The risk of variant genotypes *ε*2/*ε*2, *ε*2/*ε*3, *ε*2/*ε*4, *ε*3/*ε*4, and *ε*4/*ε*4 was evaluated compared with the *ε*3/*ε*3 genotype. In addition, *ε*2 versus *ε*3 and *ε*4 versus *ε*3 were also analyzed. The test of heterogeneity for selected studies was assessed by *I*^2^-statistics.[@b16-cia-12-1941],[@b17-cia-12-1941] When a significant heterogeneity (no heterogeneity: *I*^2^\<25%; moderate heterogeneity: *I*^2^=25%--50%; significant heterogeneity: *I*^2^≥50%) appeared across the selected studies, the random effects model was used.[@b18-cia-12-1941],[@b19-cia-12-1941] Otherwise, the fixed effects model was adopted. To estimate whether our results were stable, a sensitivity analysis was performed by sequentially omitting each individual study and recalculating the remaining studies. The potential publication bias was examined by Begg's tests and funnel plot.[@b20-cia-12-1941] Statistical tests were carried out by Stata software v12.0 (Stata Corp, College Station, TX, USA).

Results
=======

Characteristics of eligible studies
-----------------------------------

The initial search identified 721 references. Of those, 18 publications[@b21-cia-12-1941]--[@b38-cia-12-1941] with 2,004 cases and 3,705 controls were included in our meta-analysis. The study selection process was shown in [Figure 1](#f1-cia-12-1941){ref-type="fig"}. Of all eligible studies focusing on the association between ApoE polymorphism and MCI susceptibility, 14 studies were performed in China,[@b21-cia-12-1941],[@b23-cia-12-1941]--[@b35-cia-12-1941] two in Caucasians,[@b22-cia-12-1941],[@b37-cia-12-1941] one in Brazil,[@b36-cia-12-1941] and one in India.[@b38-cia-12-1941] The genotype distributions of all control samples are consistent with the HWE. The detailed characteristics of selected studies are summarized in [Table 1](#t1-cia-12-1941){ref-type="table"}.

Quantitative synthesis
----------------------

The overall results showed that ApoE variants were associated with an increased risk of MCI in the following genetic models: *ε*4 versus *ε*3: OR =2.38, 95% CI: 2.11--2.68; *ε*4/*ε*4 versus *ε*3/*ε*3: OR =4.45, 95% CI: 3.06--6.48; *ε*2/*ε*4 versus *ε*3/*ε*3: OR =2.57, 95% CI: 1.77--3.73; *ε*3/*ε*4 versus *ε*3/*ε*3: OR =2.31, 95% CI: 1.99--2.69 ([Figure 2](#f2-cia-12-1941){ref-type="fig"} and [Table 2](#t2-cia-12-1941){ref-type="table"}). The results also showed that a slight protection was observed in *ε*2/*ε*3 versus *ε*3/*ε*3 analysis (OR =0.80, 95% CI: 0.66--0.97, [Table 2](#t2-cia-12-1941){ref-type="table"}). However, no association was detected in *ε*2 versus *ε*3 (OR =0.90, 95% CI: 0.77--1.05, [Figure 3](#f3-cia-12-1941){ref-type="fig"} and [Table 2](#t2-cia-12-1941){ref-type="table"}) and *ε*2/*ε*2 versus *ε*3/*ε*3 models (OR =0.91, 95% CI: 0.50--1.65, [Table 2](#t2-cia-12-1941){ref-type="table"}). In the stratified analysis based on ethnicity, we only analyzed the Chinese population due to rare publications on other ethnicities. Stratified analysis indicated that ApoE variants contributed to increase the risk of MCI in Chinese population (*ε*4 versus *ε*3: OR =2.52, 95% CI: 2.19--2.90; *ε*4/*ε*4 versus *ε*3/*ε*3: OR =5.45, 95% CI: 3.41--8.70; *ε*2/*ε*4 versus *ε*3/*ε*3: OR =2.59, 95% CI: 1.74--3.86; *ε*3/*ε*4 versus *ε*3/*ε*3: OR =2.34, 95% CI: 1.97--2.79, [Table 2](#t2-cia-12-1941){ref-type="table"}). No significant association was observed in two genetic models in Chinese population (*ε*2 versus *ε*3: OR =0.92, 95% CI: 0.78--1.09 and *ε*2/*ε*2 versus *ε*3/*ε*3: OR =1.04, 95% CI: 0.55--1.99, [Table 2](#t2-cia-12-1941){ref-type="table"}). It is noted that only slight protection was found under the comparison of *ε*2/*ε*3 versus *ε*3/*ε*3 genotype (OR =0.79, 95% CI: 0.64--0.98, [Table 2](#t2-cia-12-1941){ref-type="table"}) in Chinese population. In addition, no significant heterogeneity was detected in all genetic models ([Table 2](#t2-cia-12-1941){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

The stability of results is assessed by sequential omission of one study in turn. The pooled ORs are not materially altered ([Figures 4](#f4-cia-12-1941){ref-type="fig"} and [5](#f5-cia-12-1941){ref-type="fig"}), indicating that no single study could influence the stability of the results of this meta-analysis.

To assess the potential publications bias of studies, Begg's test was performed. For *ε*2 versus *ε*3, the funnel plot seemed nearly symmetry ([Figure 6](#f6-cia-12-1941){ref-type="fig"}), and the *P*-value for Begg's test (*P*=0.820) suggests no obvious publication bias. With regard to *ε*4 versus *ε*3 model, the funnel plot seemed asymmetry ([Figure 7](#f7-cia-12-1941){ref-type="fig"}), and the *P*-value (*P*\<0.05) revealed that a significant publication existed. By using the trim and fill method, six studies are filled for *ε*4 versus *ε*3 model, in order to balance the funnel plot. The adjusted risk estimate for *ε*4 versus *ε*3 was 2.255 (95% CI: 2.141--2.370, *P*\<0.001), remaining statistically significant, suggesting that the results of our meta-analysis was stable.

Discussion
==========

The ApoE gene is one of the most studied genes for associations with MCI susceptibility. The ApoE polymorphism has been associated with an increased risk of several CNS disorders. Although the exact mechanisms by which ApoE variants lead to MCI are still unclear, ApoE may have many important functions for developing MCI. Studies showed that carrying *ε*4 allele could increase the aggregation and deposition of amyloid β-protein (Aβ) in brain compared to other polymorphisms.[@b39-cia-12-1941],[@b40-cia-12-1941] In addition, higher tau levels, lower CSF Aβ 42 levels, and greater brain atrophy were found in the *ε*4 allele carriers than noncarriers.[@b41-cia-12-1941] ApoE gene polymorphisms also play an important role in the neuronal repair,[@b42-cia-12-1941] cerebral glucose metabolism,[@b43-cia-12-1941] lipid metabolism,[@b44-cia-12-1941] maintaining synaptic plasticity,[@b45-cia-12-1941],[@b46-cia-12-1941] neuroinflammation,[@b47-cia-12-1941]--[@b49-cia-12-1941] and neurogenesis.[@b50-cia-12-1941]--[@b52-cia-12-1941] Those functions of ApoE may also be involved in the pathology of MCI.

In 1998, Smith et al[@b53-cia-12-1941] first demonstrated that ApoE gene *ε*4 allele was highly associated with an increased risk of MCI. Subsequently, a number of studies were performed to estimate the association of ApoE gene polymorphism with MCI. However, the results were still controversial. To further explore and evaluate the association between ApoE gene polymorphism and MCI susceptibility, we performed a meta-analysis of 2,004 cases and 3,705 controls. Overall, we detected that ApoE polymorphism contributed to increase the risk of MCI under the *ε*4 versus *ε*3, *ε*4/*ε*4 versus *ε*3/*ε*3, *ε*2/*ε*4 versus *ε*3/*ε*3, and *ε*3/*ε*4 versus *ε*3/*ε*3 genetic models. However, no association was found under the *ε*2 versus *ε*3 and *ε*2/*ε*2 versus *ε*3/*ε*3 genetic models. Furthermore, a slight protection was discovered under the *ε*2/*ε*3 versus *ε*3/*ε*3 genetic model. In the stratified analysis, we analyzed only the Chinese population, and the results were similar to overall population. Interestingly, we found that ApoE *ε*4 allele increased MCI risk in a dose-dependent manner (*ε*4 versus *ε*3: OR =2.52, 95% CI: 2.19--2.90; *ε*4/*ε*4 versus *ε*3/*ε*3: OR =5.45, 95% CI: 3.41--8.70), which was in accordance with several previous studies.[@b23-cia-12-1941],[@b24-cia-12-1941],[@b54-cia-12-1941],[@b55-cia-12-1941] No significant heterogeneity was identified in any genetic models.

In this meta-analysis, we detected a potential publication bias in the *ε*4 versus *ε*3 genetic model, which may generate false-positive results. By using the trim and fill method, the results suggested that six studies were needed to balance the asymmetric funnel plot and the adjusted results for *ε*4 versus *ε*3 remained significant (OR =2.255, 95% CI: 2.141--2.370, *P*\<0.001), indicating that the results were stable. It was emphasized that the potential publications may partly influence the results, but not deeply.

There are several limitations in the present meta-analysis. First, our meta-analysis was based predominantly on Chinese population. Only one study focused on the African, two studies on Caucasians, and one study on Indian, which might generate a partial result. Second, due to rare publications on other ethnicities, we analyzed only the Chinese population and other ethnicities were not evaluated in our meta-analysis. Finally, MCI is a complex disease. Gene--gene or gene--environment factors play an important role in MCI susceptibility. However, most selected studies did not analyze those interacted factors.

Conclusion
==========

Our meta-analysis first showed that ApoE *ε*4 allele, *ε*4*ε*4, *ε*4*ε*3, and *ε*2*ε*4 genotypes were the risk factors of MCI, while *ε*2*ε*3 genotype was a protective factor, especially in Chinese population. We boldly supposed that ApoE polymorphism may be used as a useful potential therapeutic target to prevent, delay, or revert the healthy elderly to MCI conversion. Considering several limitations mentioned above, the results should be interpreted with caution. Further well-designed studies with larger sample size are required to validate the association between ApoE polymorphism and MCI risk.

This work was supported by the National Natural Science Foundation of China (Grant No 81671305), key Development Projects of Shandong Province (Grant No 2015GSF118177), and the Major Science and Technology Project of Independent Innovation of Qingdao (Grant No 14-6-1-6-zdzx).

**Disclosure**

The authors report no conflicts of interest in this work.

![Flow diagram of the article selection process.](cia-12-1941Fig1){#f1-cia-12-1941}
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![Forest plot for the association of ApoE polymorphism with MCI susceptibility in the overall populations (*ε*2 vs *ε*3).\
**Abbreviations:** ApoE, apolipoprotein E; MCI, mild cognitive impairment; OR, odds ratio; CI, confidence interval.](cia-12-1941Fig3){#f3-cia-12-1941}

![Sensitivity analysis of the summary of OR coefficients in the overall populations (*ε*4 vs *ε*3).\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](cia-12-1941Fig4){#f4-cia-12-1941}

![Sensitivity analysis of the summary of OR coefficients in the overall populations (*ε*2 vs *ε*3).\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](cia-12-1941Fig5){#f5-cia-12-1941}

![Begg's funnel plot of ApoE polymorphism with MCI susceptibility in overall populations (*ε*2 vs *ε*3).\
**Abbreviations:** ApoE, apolipoprotein E; MCI, mild cognitive impairment; OR, odds ratio; SE, standard error.](cia-12-1941Fig6){#f6-cia-12-1941}

![Begg's funnel plot of ApoE polymorphism with MCI susceptibility in overall populations (*ε*4 vs *ε*3).\
**Abbreviations:** ApoE, apolipoprotein E; MCI, mild cognitive impairment; OR, odds ratio; SE, standard error.](cia-12-1941Fig7){#f7-cia-12-1941}

###### 

Characteristics of the selected studies

  Study                                Year   Geographical location   Sample size (case/control)   Case   Control                                                                                       
  ------------------------------------ ------ ----------------------- ---------------------------- ------ --------- ---- ----- ---- --- ----- ----- ---- ---- ----- ---- ----- ----- ---- ----- ------- -----
  Wang et al[@b21-cia-12-1941]         2002   China (Heifei)          28/30                        2      9         7    6     3    1   20    24    12   1    4     2    18    4     1    8     44      8
  Gamarra et al[@b22-cia-12-1941]      2015   Spain                   124/125                      20     66        2    119   9    0   108   313   11   0    49    2    170   22    2    51    411     28
  Wang et al[@b23-cia-12-1941]         2014   China (Wuzhong)         216/743                      1      24        1    135   17   3   27    311   24   6    34    2    580   105   16   48    1,299   139
  Borenstein et al[@b24-cia-12-1941]   2010   China (Shanghai)        30/32                        2      5         2    20    1    0   11    46    3    0    2     1    23    6     0    3     54      7
  Wang et al[@b25-cia-12-1941]         2014   China (Beijing)         56/75                        0      23        1    26    3    3   24    78    10   0    8     3    51    12    1    11    122     17
  Chen et al[@b26-cia-12-1941]         2016   China (Shanghai)        583/1,149                    27     129       16   353   56   2   199   891   76   8    156   21   802   154   8    193   1,914   191
  Chen et al[@b27-cia-12-1941]         2016   China (Ningbo)          64/54                        5      20        0    35    4    0   30    94    4    0    7     0    37    10    0    7     91      10
  Hu et al[@b28-cia-12-1941]           2005   China (Guangxi)         16/96                        1      3         1    10    1    0   6     24    2    0    4     1    79    7     5    5     169     18
  Xu et al[@b29-cia-12-1941]           2009   China (Guangzhou)       120/120                      2      36        1    65    16   0   41    182   17   1    16    1    81    21    0    19    199     22
  Lv and Zhong[@b30-cia-12-1941]       2012   China (Shanghai)        84/106                       3      20        2    52    6    1   28    130   10   0    15    1    76    12    2    16    179     15
  He et al[@b31-cia-12-1941]           2015   China (Nanchang)        120/120                      4      23        1    79    12   1   32    193   15   0    17    1    83    17    2    18    200     22
  Ye and Zhang[@b32-cia-12-1941]       2008   China (Wuhan)           56/89                        2      15        5    31    3    0   24    80    8    1    11    1    64    12    0    14    151     13
  He et al[@b33-cia-12-1941]           2015   China (Shenyang)        63/60                        6      18        1    32    6    0   31    88    7    2    8     1    39    10    0    13    96      11
  Yue et al[@b34-cia-12-1941]          2013   China (Nanjing)         111/90                       4      25        3    66    13   0   36    170   16   0    8     0    69    13    0    8     159     13
  Chen et al[@b35-cia-12-1941]         2011   China (Guiyang)         76/152                       9      18        28   13    6    2   64    50    38   10   29    38   57    14    4    87    157     60
  Kerr et al[@b36-cia-12-1941]         2016   Brazil                  43/144                       1      14        1    25    1    1   17    65    4    1    31    2    91    18    1    35    231     22
  Lanni et al[@b37-cia-12-1941]        2012   Italy                   70/248                       2      18        2    41    7    0   24    107   9    0    27    0    201   20    0    27    449     20
  Jairani et al[@b38-cia-12-1941]      2016   India                   87/152                       4      40        2    35    6    0   50    116   8    20   34    3    82    8     5    81    206     21

###### 

Meta-analysis of apolipoprotein E gene polymorphism and MCI risk

  Genetic models               Variables   Number of studies   Test of association   Test of heterogeneity                    
  ---------------------------- ----------- ------------------- --------------------- ----------------------- --------- ------ ---
  *ε*2/*ε*2 vs *ε*3/*ε*3       Overall     18                  0.91                  0.50--1.65              0.758     0      F
  Chinese                      14          1.04                0.55--1.99            0.902                   0         F      
  *ε*2/*ε*4 vs *ε*3/*ε*3       Overall     18                  2.57                  1.77--3.73              \<0.001   0      F
  Chinese                      14          2.59                1.74--3.86            \<0.001                 0         F      
  *ε*2/*ε*3 vs *ε*3/*ε*3       Overall     18                  0.8                   0.66--0.97              0.026     0      F
  Chinese                      14          0.79                0.64--0.98            0.03                    0         F      
  *ε*3/*ε*4 vs *ε*3/*ε*3       Overall     18                  2.31                  1.99--2.69              \<0.001   0      F
  Chinese                      14          2.34                1.97--2.79            \<0.001                 5.8       F      
  *ε*4/*ε*4 vs *ε*3/*ε*3       Overall     18                  4.45                  3.06--6.48              \<0.001   39.6   F
  Chinese                      14          5.45                3.41--8.70            \<0.001                 0         F      
  *ε*4 allele vs *ε*3 allele   Overall     18                  2.38                  2.11--2.68              \<0.001   42.8   F
  Chinese                      14          2.52                2.19--2.90            \<0.001                 0         F      
  *ε*2 allele vs *ε*3 allele   Overall     18                  0.9                   0.77--1.05              0.179     32.2   F
  Chinese                      14          0.92                0.78--1.09            0.346                   30.2      F      

**Note:** *P*-value corresponding to the *Z*-test for the summary effect estimate (*P*\<0.05 considered statistically significant).

**Abbreviations:** F, fixed effects model; OR, odds ratio; CI, confidence interval; *I*^2^, heterogeneity index; MCI, mild cognitive impairment.
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